Guest: Alexander Zhavoronkov
Founder, CEO and CBO at Insilico Medicine
Linkedin: www.linkedin.com/in/zhavoronkov/
Website: https://insilico.com/
______________________
What if the biggest breakthrough in longevity wasn’t a single drug… but a faster way to discover them?
In this episode, Phil Newman and Dr Nina Patrick sit down with Alex Zhavoronkov, founder and CEO of Insilico Medicine, to explore how artificial intelligence is reshaping biotechnology, from target discovery to clinical trials.
They discuss why advanced diagnostics may currently outperform most longevity interventions, how AI platforms design entirely new molecules, and why no longevity drug has yet proven efficacy in humans despite promising animal data. Alex explains how modern biotech companies balance aging research with traditional disease treatment, and why the first real longevity therapeutics will likely emerge as side benefits of drugs built for specific conditions.
Together, they examine the reality behind GLP-1 drugs, long term safety testing, and the limits of predictive algorithms. The conversation also looks ahead to brain computer interfaces, multimodal biological models, and the possibility of pharmaceutical superintelligence accelerating medical progress within the next decade.
In this episode, you’ll learn:
If you want to understand how artificial intelligence is changing medicine, what real longevity therapeutics may look like, and why the future of healthspan depends on both biology and computation, this is a conversation you don’t want to miss.
Subscribe for weekly episodes exploring longevity science, emerging biotech, and the innovations shaping the future of human health.
______________________
Hosts:
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: https://qrco.de/bgXpKn
